Susana Vives

Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia

Pau Montesinos, Christian Récher, Susana Vives et al. · New England Journal of Medicine · 2022 · 448 citations · Full text

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

Albert Oriol, Susana Vives, Jesús María Hernández‐Rivas et al. · Haematologica · 2010 · 289 citations · Full text

Detailed Characterization of Mesenchymal Stem/Stromal Cells from a Large Cohort of AML Patients Demonstrates a Definitive Link to Treatment Outcomes

Rafael Díaz de la Guardia, Belén López‐Millán, Jessie R. Lavoie et al. · Stem Cell Reports · 2017 · 97 citations · Full text

Cell Therapy, Developmental Biology, Detailed Characterization +10

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo

Matteo Libero Baroni, Diego Sánchez‐Martínez, Francisco Gutiérrez Agüera et al. · Journal for ImmunoTherapy of Cancer · 2020 · 63 citations · Full text

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study

David Martínez‐Cuadrón, Juan Eduardo Megías‐Vericat, Josefina Serrano et al. · Blood Advances · 2021 · 61 citations · Full text

Surgical Oncology, Mixed-phenotype Acute Leukemia, Pathology +18